XTRA:SRT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide.


Snowflake Analysis

Moderate growth potential with acceptable track record.


Similar Companies

Share Price & News

How has Sartorius's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SRT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.7%

SRT

0.9%

DE Medical Equipment

2.1%

DE Market


1 Year Return

53.3%

SRT

20.3%

DE Medical Equipment

2.1%

DE Market

Return vs Industry: SRT exceeded the German Medical Equipment industry which returned 20.4% over the past year.

Return vs Market: SRT exceeded the German Market which returned 3% over the past year.


Shareholder returns

SRTIndustryMarket
7 Day3.7%0.9%2.1%
30 Day-3.4%-2.8%-0.8%
90 Day22.2%15.1%20.1%
1 Year53.5%53.3%21.8%20.3%4.2%2.1%
3 Year200.6%197.4%121.8%117.1%3.7%-4.7%
5 Year491.3%478.5%248.4%234.4%10.7%-4.0%

Price Volatility Vs. Market

How volatile is Sartorius's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sartorius undervalued compared to its fair value and its price relative to the market?

110.38x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: SRT (€253) is trading above our estimate of fair value (€94.37)

Significantly Below Fair Value: SRT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SRT is poor value based on its PE Ratio (110.4x) compared to the Medical Equipment industry average (53x).

PE vs Market: SRT is poor value based on its PE Ratio (110.4x) compared to the German market (21.1x).


Price to Earnings Growth Ratio

PEG Ratio: SRT is poor value based on its PEG Ratio (6.9x)


Price to Book Ratio

PB vs Industry: SRT is overvalued based on its PB Ratio (21.4x) compared to the DE Medical Equipment industry average (4.5x).


Next Steps

Future Growth

How is Sartorius forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

16.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SRT's forecast earnings growth (16.1% per year) is above the savings rate (0.2%).

Earnings vs Market: SRT's earnings (16.1% per year) are forecast to grow slower than the German market (22.4% per year).

High Growth Earnings: SRT's earnings are forecast to grow, but not significantly.

Revenue vs Market: SRT's revenue (10.9% per year) is forecast to grow faster than the German market (5.9% per year).

High Growth Revenue: SRT's revenue (10.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SRT's Return on Equity is forecast to be high in 3 years time (24.8%)


Next Steps

Past Performance

How has Sartorius performed over the past 5 years?

18.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SRT has high quality earnings.

Growing Profit Margin: SRT's current net profit margins (8.7%) are lower than last year (9.3%).


Past Earnings Growth Analysis

Earnings Trend: SRT's earnings have grown by 18.9% per year over the past 5 years.

Accelerating Growth: SRT's earnings growth over the past year (8.2%) is below its 5-year average (18.9% per year).

Earnings vs Industry: SRT earnings growth over the past year (8.2%) underperformed the Medical Equipment industry 8.2%.


Return on Equity

High ROE: SRT's Return on Equity (20.3%) is considered high.


Next Steps

Financial Health

How is Sartorius's financial position?


Financial Position Analysis

Short Term Liabilities: SRT's short term assets (€927.0M) exceed its short term liabilities (€663.2M).

Long Term Liabilities: SRT's short term assets (€927.0M) do not cover its long term liabilities (€1.1B).


Debt to Equity History and Analysis

Debt Level: SRT's debt to equity ratio (87.7%) is considered high.

Reducing Debt: SRT's debt to equity ratio has increased from 55.8% to 87.7% over the past 5 years.

Debt Coverage: SRT's debt is well covered by operating cash flow (38.3%).

Interest Coverage: SRT's interest payments on its debt are well covered by EBIT (58.2x coverage).


Balance Sheet


Next Steps

Dividend

What is Sartorius's current dividend yield, its reliability and sustainability?

0.14%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: SRT's dividend (0.14%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.26%).

High Dividend: SRT's dividend (0.14%) is low compared to the top 25% of dividend payers in the German market (3.8%).


Stability and Growth of Payments

Stable Dividend: SRT is not paying a notable dividend for the German market, therefore no need to check if payments are stable.

Growing Dividend: SRT is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: SRT is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SRT's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Joachim Kreuzburg (55yo)

17.17yrs

Tenure

€2,061,000

Compensation

Dr. rer. pol. Joachim Kreuzburg serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech GmbH. Dr. rer. pol. Kreuzburg has been the Chairman of Executive Board at Sartorius Aktiengese ...


CEO Compensation Analysis

Compensation vs Market: Joachim's total compensation ($USD2.33M) is below average for companies of similar size in the German market ($USD5.21M).

Compensation vs Earnings: Joachim's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Joachim Kreuzburg
Chairman of Executive Board & CEO17.17yrs€2.06mno data
Rainer Lehmann
CFO, Member of Executive Board and Head of Finance2.5yrs€922.00kno data
John Mackay
Head of Lab Products & Services Division and Member of Executive Board1.5yrs€991.00kno data
René Fáber
Head of Bioprocess Solutions Division & Member of Executive Board1.5yrs€861.00kno data
Petra Kirchhoff
Head of Corporate Communications & Investor Relations and Member of Supervisory Boardno data€56.00kno data
Manfred Werner
Senior Vice President of Administration Organization & Auditingno datano datano data
Mei Wang
Head of Production - Chinano datano datano data
Patricia Spannagel
Head of Quality Assurance - Mechatronics Division Goettingenno datano datano data
Rashid Maqbool
Head of Production & Certification Department - Denver USAno datano datano data
Manohar Kuppusami
Head of Production Department - Indiano datano datano data

2.5yrs

Average Tenure

51yo

Average Age

Experienced Management: SRT's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Petra Kirchhoff
Head of Corporate Communications & Investor Relations and Member of Supervisory Boardno data€56.00kno data
Klaus Trützschler
Member of Supervisory Board8.67yrs€107.00kno data
Uwe Bretthauer
Member of Supervisory Boardno data€92.00kno data
Annette Becker
Member of the Supervisory Boardno data€56.00kno data
Michael Dohrmann
Member of the Supervisory Board13.58yrs€56.00kno data
Lothar Kappich
Chairman of Supervisory Board3yrs€246.00k27.37% 5.2b
Daniela Favoccia
Member of Supervisory Board3.25yrs€53.00kno data
Thomas Scheper
Member of the Supervisory Board8.25yrs€45.00kno data
Karoline Kleinschmidt
Member of the Supervisory Board8.25yrs€56.00kno data
Manfred Zaffke
Vice Chairman of the Supervisory Board6.33yrs€137.00kno data

8.3yrs

Average Tenure

63yo

Average Age

Experienced Board: SRT's board of directors are considered experienced (8.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sartorius Aktiengesellschaft's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sartorius Aktiengesellschaft
  • Ticker: SRT
  • Exchange: XTRA
  • Founded: 1870
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €18.990b
  • Shares outstanding: 68.39m
  • Website: https://www.sartorius.com

Number of Employees


Location

  • Sartorius Aktiengesellschaft
  • Otto-Brenner-Strasse 20
  • Göttingen
  • Lower Saxony
  • 37079
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SART.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 1992
SRTDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1992
SRT3DB (Deutsche Boerse AG)Preference SharesDEEURJan 1992
SRTXTRA (XETRA Trading Platform)YesOrdinary SharesDEEURJan 1992
SRT3XTRA (XETRA Trading Platform)Preference SharesDEEURJan 1992
0NIQLSE (London Stock Exchange)YesOrdinary SharesGBEURJan 1992
0NIRLSE (London Stock Exchange)Preference SharesGBEURJan 1992
SUVP.FOTCPK (Pink Sheets LLC)Preference SharesUSUSDJan 1992
SRT3DBATS-CHIXE (BATS 'Chi-X Europe')Preference SharesGBEURJan 1992
SRT3SWX (SIX Swiss Exchange)Preference SharesCHCHFJan 1992
SRT3WBAG (Wiener Boerse AG)Preference SharesATEURJan 1992
SRTETLX (Eurotlx)YesOrdinary SharesITEURJan 1992
SRT3ETLX (Eurotlx)Preference SharesITEURJan 1992

Biography

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers live cell analysis system, and cell analysis reagents and consumables; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors. It also provides lab filtration and purification devices; sterile and virus filtration, crossflow filtration, harvesting, prefiltration, membrane chromatography, air/gas filtration, and integrity testing devices; and liquid storage and shipping, freeze and thaw, mixing, proven integrity, transferring and sampling, connecting and disconnecting, and final filling management products. In addition, the company offers process control and data analytics products, such as process analyzers, automation modules, and data analytics and chemometrics; and microbiology products, and lab water purification systems. Further, it provides lab balances, mass comparators and metrology, moisture analyzers, specialty weighing solutions, weighing accessories, weights/weight sets, paint mixing solutions, and OEM weigh cells; and OEM membrane and device, pipetting and dispensing, and connectivity solutions. Additionally, the company offers bioprocess development engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, cannabis testing, food and beverage, environmental, and paint mixing industries. The company was founded in 1870 and is headquartered in Göttingen, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/07 20:51
End of Day Share Price2020/07/07 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.